Association of antiepileptic drugs with nontraumatic fractures: A population-based analysis

Archives of Neurology

Volumn 68, Issue 1, 2011, Pages 107-112

  Jetté, Nathalie ^a   Lix, Lisa M ^b   Metge, Colleen J ^c,d   Prior, Heather J ^c   McChesney, Jane ^a   Leslie, William D ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; EPILEPSY; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ANTICONVULSANTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES;

EID: 78651339196     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.341     Document Type: Article

References (38)

1. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10(2):92-96.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733.
3. Goeree R, O'Brien B, Pettitt D, Cuddy L, Ferraz M, Adachi J. An assessment of the burden of illness due to osteoporosis in Canada. J Soc Obstet Gynaecologists Canada. 1996;18(suppl July):15-24.
4. Vanness D. Estimating the opportunity costs of osteoporosis in the United States. Top Geriatric Rehab. 2005;21(1):4-16.
5. Jacobs-Kosmin D, Hobar C, Chanmugam S. Metabolic and bone disease: osteoporosis. http://emedicine.medscape.com/article/330598-print. Accessed October 5, 2009.
6. Hauser WA. Incidence and prevalence. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Vol 1. Philadelphia, PA: Lippincott-Raven Publishers; 1998:45-57.
7. Lyngstad-Brechan MA, Taubøll E, Nakken KO, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest. 2008;68(8):759-766.
8. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004;62(11):2051-2057.
9. Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES; Osteoporotic Fractures in Men (MrOS) Study Research Group. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology. 2008;71(10):723-730.
10. Espallargues M, Sampietro-Colom L, Estrada MD, et al. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteoporos Int. 2001;12(10):811-822.
11. Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia. 2005;46(2):304-310.
12. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology. 2006;66(9):1318-1324.
13. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45(11):1330-1337. (Pubitemid 39470036)
14. Roos NP. Establishing a population data-based policy unit. Med Care. 1999;37(6)(suppl):JS15-JS26.
15. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone. 2007;40(6):1595-1601.
16. Leslie WD, Tsang JF, Caetano PA, Lix LM; Manitoba Bone Density Program. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab. 2007;92(1):77-81.
17. Starfield B, Weiner J, Mumford L, Steinwachs D. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res. 1991;26(1):53-74.
18. Kozyrskyj AL, Mustard CA. Validation of an electronic, population-based prescription database. Ann Pharmacother. 1998;32(11):1152-1157.
19. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). World Health Organization Web site. http://www.who.int/classifications/atcddd/ en/. Accessed November 10, 2010.
20. van Staa TP, Leufkens HG, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone. 2002;31(4):508-514.
21. Manitoba Centre for Health Policy. Concept Dictionary 2007: income quintiles based on the 1996 census. University of Manitoba Web site. http://umanitoba.ca/faculties/medicine/units/community-health-sciences/ departmental-units/mchp/resources/concept-dictionary.html. Accessed October 23, 2009.
22. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118(12):1414.
23. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586-1593.
24. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand. 2005;112(5):277-286.
25. Barbour KE, Zmuda JM, Strotmeyer ES, et al; Osteoporotic Fractures in Men (MrOS) Research Group. Correlates of trabecular and cortical volumetric bone mineral density of the radius and tibia in older men: the Osteoporotic Fractures in Men Study. J Bone Miner Res. 2010;25(5):1017-1028.
26. Cauley JA, Fullman RL, Stone KL, et al; Mr. OS Research Group. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005;16(12):1525-1537.
27. Hill DD, Cauley JA, Sheu Y, et al. Correlates of bone mineral density in men of African ancestry: the Tobago bone health study. Osteoporos Int. 2008;19(2):227-234.
28. Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a risk factor for fractures. Calcif Tissue Int. 2009;84(2):103-111.
29. Orwoll ES, Bevan L, Phipps KR. Determinants of bone mineral density in older men. Osteoporos Int. 2000;11(10):815-821.
30. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA; Study of Osteoporotic Fractures Research Group. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Lancet. 1999;354(9183):971-975.
31. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24(3):581-589.
32. Bauer DC, Browner WS, Cauley JA, et al; The Study of Osteoporotic Fractures Research Group. Factors associated with appendicular bone mass in older women. Ann Intern Med. 1993;118(9):657-665.
33. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol. 1994;139(11):1107-1115.
34. Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM. Thiazide effect on the mineral content of bone. N Engl J Med. 1983;309(6):344-347.
35. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008;22(7):2465-2475.
36. Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008;28(4):384-391.
37. Richards JB, Papaioannou A, Adachi JD, et al; Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194.
38. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure. 2008;17(2):181-186.